The estimated Net Worth of Randy H Thurman is at least $1.27 Million dollars as of 29 September 2022. Mr. Thurman owns over 40,255 units of Outlook Therapeutics Inc stock worth over $282,993 and over the last 12 years he sold OTLK stock worth over $634,829. In addition, he makes $348,000 as Executive Chairman of the Board at Outlook Therapeutics Inc.
Randy has made over 8 trades of the Outlook Therapeutics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 40,255 units of OTLK stock worth $100,638 on 29 September 2022.
The largest trade he's ever made was exercising 40,255 units of Outlook Therapeutics Inc stock on 29 September 2022 worth over $100,638. On average, Randy trades about 3,250 units every 103 days since 2012. As of 29 September 2022 he still owns at least 40,255 units of Outlook Therapeutics Inc stock.
You can see the complete history of Mr. Thurman stock trades at the bottom of the page.
Ralph H. Thurman serves as Executive Chairman of the Board of the Company. He is currently a senior advisor at BC Partners, a private equity firm, and is also currently a member of the Board of Directors at Allscripts, Inc. and Zest Dental, Inc. In the span of his career, Mr. Thurman has previously been the President of both Rorer and Rhone-Polenc Rorer Pharmaceuticals, CEO of Corning Life Sciences, and Chairman and CEO of VIASYS Healthcare, Inc., as well as a member of the board for over 15 public and private companies.
As the Executive Chairman of the Board of Outlook Therapeutics Inc, the total compensation of Randy Thurman at Outlook Therapeutics Inc is $348,000. There are 3 executives at Outlook Therapeutics Inc getting paid more, with Lawrence Kenyon having the highest compensation of $1,863,900.
Randy Thurman is 70, he's been the Executive Chairman of the Board of Outlook Therapeutics Inc since 2018. There are 1 older and 12 younger executives at Outlook Therapeutics Inc. The oldest executive at Outlook Therapeutics Inc is Ralph H. Thurman, 72, who is the Independent Exec. Chairman.
Randy's mailing address filed with the SEC is C/O OUTLOOK THERAPEUTICS, INC., 485 ROUTE 1 SOUTH, BUILDING F, SUITE 320, ISELIN, NJ, 08830.
Over the last 6 years, insiders at Outlook Therapeutics Inc have traded over $1,453,842 worth of Outlook Therapeutics Inc stock and bought 29,698,365 units worth $33,411,235 . The most active insiders traders include Pte Ltd.Pillai Arun Kumar S..., Ghiath M.Gms Ventures & Inv..., and Ventures Llc Syntone. On average, Outlook Therapeutics Inc executives and independent directors trade stock every 43 days with the average trade being worth of $11,985,869. The most recent stock trade was executed by Ventures Llc Syntone on 15 April 2024, trading 714,286 units of OTLK stock currently worth $5,021,431.
overview oncobiologics is a pure-play complex biosimilar company focused on technically challenging and commercially attractive monoclonal antibodies (mabs), in the therapeutic areas of immunology and oncology. our strategy is to cost-effectively develop technically challenging biosimilars on an accelerated timeline, which we believe is fundamental to our success and positions us to be a leading biosimilar company. we have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our biosymphony™ platform. oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mab biosimilars. pipeline oncobiologics is actively working on eight biosimilar candidates. the company’s most advanced assets, ons-3010 (a biosimilar of humira®) and ons-1045 (a biosimilar of avastin®) have both successfully completed phase i trials and phase 3 t
Outlook Therapeutics Inc executives and other stock owners filed with the SEC include: